HER2-Low Breast Cancer: Pathological and Clinical LandscapePaolo Tarantino, Giuseppe Curigliano, Frédérique Penault‐Llorca et al.|Journal of Clinical Oncology|2020Cited by 801
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real lifeStefania Morganti, Giuseppe Curigliano, Paolo Tarantino et al.|Critical Reviews in Oncology/Hematology|2018Cited by 149
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A reviewLuca Mazzarella, Giuseppe Curigliano, Bruno A. Duso et al.|European Journal of Cancer|2019Cited by 99
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Matthew Dankner, Sarah M. Maritan et al.|The Breast|2023Cited by 25
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.Anna-Maria Lazaratos, Matthew Dankner, Sarah M. Maritan et al.|Journal of Clinical Oncology|2023Cited by 0